ASSOCIATION OF BIOMOLECULES OF SECRETORY ACTIVITY OF VISCERAL ADIPOCYTES WITH ELECTROPHYSIOLOGICAL SIGNS OF METABOLIC DISORDERS OF MYOCARDIUM IN CORONARY ATHEROSCLEROSIS AND METABOLIC SYNDROME

Aim. Assessment in the blood of coronary atherosclerosis (CA) patients with metabolic syndrome (MS), of biomarkers associated with secretory activity of visceral adipocytes, and search for their associations with electrophysiological signs of metabolic cardiomyopathy (MCP).

Material and methods. Totally, 123 males included, age 41-79 y. o., with CA verified by coronary arteriography, and with stable angina. ECG recording completed at rest in 12 standard leads with Minessota coding. On ECG, the markers of MCP were analyzed: QT interval duration, corrected QT, ST shift above isoline >0,5 mm, ST depression below isoline >0,5 mm of non-ischemic type, T-wave changes, syndrome TV1>TV6, signs of the left ventricle hypertrophy (LVH), disorders of rhythm and conduction. The components and signs of MC were analyzed: waist circumference, arterial pressure, levels of lipids and glucose in blood. In the blood, by immune enzyme method, the following markers were measured: tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6), leptin, resistin, adiponectin, C-reactive protein.

Results. Metabolic syndrome in general was found in 86 men (69,9%) with abdominal obesity and CA. Level of TNF-alpha was increased in 47,2% males, IL-6 level — in 72,4%, hsCRBP — in 64,2%, leptin — in 47%, resistin — in 54%, adiponectin was decreased in 22% cases. In MS males resistin concentration was 1,6 times higher. In subgroup of the persons with ECG signs of LVH 76,5% of males had MS, and adiponectin was lower 1,3 times comparing to non-LVH subgroup. Level of TNF-alpha in males with elevated ST was 1,77 times higher than in those non-ST-elevation. In subgroup of males with TV1>TV6 syndrome the level of resistin was higher 1,4 times comparing to those with no TV1>TV6 syndrome. In subgroup of T-wave changes 83% males had MS, and resistin level was 1,3 times higher comparing to those with no T wave changes. In subgroup of ECG signs of rhythm and conduction disorder in 78,7% of males there was MS, and levels of IL-6 and leptin were 1,6 and 1,9 times higher, respectively, comparing to those with no arrhythmias. In multifactorial regression analysis the following positive associations were found (pTV6 syndrome with resistin level (OR =1,172); T wave variability with resistin (OR =1,101).

Conclusion. The results reflect the influence of metabolic changes in the body, associated with secretory activity of visceral adipocytes, on the onset and development of not just MS, but MCP. 

1. Witteles R.M., Fowler M.B. Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. // J. Am. Coll. Cardiol., 2008; 51(2): 93-102.

2. Chumakova G.A. Veselovsky N.G., Kozarenko A.A. et al. Features of morphology, structure and function of heart in obesity. Russian cardiology journal, 2012; 4 (96): 93-99. Russian (Чумакова Г.А., Веселовская Н.Г., Козаренко А.А. и др. Особенности морфологии, структуры и функции сердца при ожирении. Российский кардиологический журнал, 2012; 4 (96): 93-99.

3. Paksoy F., Ulaş T., Bes C. et al. Corrected Qt interval in patients with metabolic syndrome. Dicle Med J. 2011; 38: 274–277.

4. Goldberger J.J., Cain M.E., Hohnloser S.H. et al. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death. A Scientific Statement From the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention. JACC. 2008; 52; 1179–1199.

5. Ferrara L.A., Cardoni O., Mancini M. et al. Metabolic syndrome and left ventricular hypertrophy in a general population. Results from the Gubbio Study. J Hum Hypertens. 2007; 21: 795–801.

6. Guerra F., Mancinelli L., Angelini L. et al. The Association of Left Ventricular Hypertrophy with Metabolic Syndrome is Dependent on Body Mass Index in Hypertensive Overweight or Obese Patients. PLoS One. 2011; 6 (1): e16630.

7. Recommendations of experts of Russian Scientific Society of Cardiology for Diagnosis and treatment of metabolic syndrome. Second revision. Russian Scientific Society of Cardiology, Moscow, 2009, 32 p. Russian (Рекомендации экспертов всероссийского научного общества кардиологов по диагностике и лечению метаболического синдрома. Второй пересмотр. Всероссийское научное общество кардиологов, Москва, 2009, 32.

8. Voevoda M.I., Ragino Yu.I., Chernjavski A.M. et al. High prevalence of metabolic syndrome in men with coronary atherosclerosis in Siberia. Russian Journal of Cardiology, 2010; № 1: 65-70. Russian (Воевода М.И., Рагино Ю.И., Чернявский А.М. и др. Высокая распространенность метаболического синдрома у мужчин с коронарным атеросклерозом в Сибири. Российский кардиологический журнал, 2010; № 1: 65-70.

9. Gruzdeva O.V., Akbasheva O.E., Borodkina D.A. et al. Correlation of obesity and adipokines at risk of developing type 2 diabetes within a year after myocardial infarction. Russian Journal of Cardiology, 2015; № 4 (120): 59-67. Russian (Груздева О.В., Акбашева О.Е., Бородкина Д.А. и др. Взаимосвязь показателей ожирения и адипокинов с риском развития сахарного диабета 2 типа через год после перенесенного инфаркта миокарда. Российский кардиологический журнал, 2015; № 4(120): 59-67.

10. Guzik T.J., Mangalat D., Korbut R. Adipocytokines novel link between inflammation and vascular function? J. Physiol. Pharmacol., 2006; 57 (4): 505–28.

11. Farvid M.S., Ng T.W., Chan D.C. et al. Association of adiponectin and resistin with adipose tissue compartments, insulin resistance and dyslipidaemia. Diabetes Obes. Metab., 2005; 7 (4): 406–13.

12. Karastergiou К., Mohamed-Ali V., Jahangiri M. at el. Adiponectin for prediction of cardiovascular risk? Br. J. Diabetes Vascular. Dis., 2009; 9: 150-154.

13. Wong C., Marwick T.H. Obesity cardiomyopathy: pathogenesis and pathophysiology. // Nat. Clin. Pract. Cardiovasc. Med., 2007; 4: 436-443.

14. Elks C.M., Francis J. Central adiposity, systemic inflammation, and the metabolic syndrome. // Curr. Hypertens. Rep., 2010; 12(2): 99-104.

15. Ragino Yu.I., Timoshenko N.A., Chernjavski A.M. et al. Association of metabolic syndrome components with electrocardiographic markers of metabolic cardiomyopathy in men with coronary atherosclerosis. Russian Journal of Cardiology, 2015, № 4: 68-72. Russian (Рагино Ю.И., Тимошенко Н.А., Чернявский А.М. и др. Связь компонентов метаболического синдрома с электрокардиографическими биомаркерами метаболической кардиомиопатии у мужчин с коронарным атеросклерозом. // Российский кардиологический журнал, 2015; № 4: 68-72.